|
| 37096575 | Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. | J Urol | 2023 |
| 36343223 | Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study. | Nutr Cancer | 2023 |
| 36441070 | A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. | Urol Oncol | 2023 |
| 37343766 | Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study. | Mod Pathol | 2023 |
| 37150667 | Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy. | Clin Genitourin Cancer | 2023 |
| 37463855 | Putting patients first to redefine prostate cancer classifications. | J Natl Cancer Inst | 2023 |
| 37400528 | Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth. | Oncogene | 2023 |
| 36710146 | A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer. | Clin Genitourin Cancer | 2023 |
| 36573929 | Point-Counterpoint: Active Surveillance Should Still Be Preferred Management for All (or Nearly All) Men With Low-risk Prostate Cancer. | | 2023 |
| 36801350 | Serial Genotyping of the Human Papillomavirus in Cervical Cancer: An Insight Into Virome Dynamics During Chemoradiation Therapy. | | 2023 |
| 36621991 | Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial. | J Urol | 2023 |
| 37479875 | Constructing time-invariant dynamic surveillance rules for optimal monitoring schedules. | | 2023 |
| 37096582 | Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. | J Urol | 2023 |
| 34993496 | Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. | HGG Adv | 2022 |
| 36369237 | Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity. | Nat Commun | 2022 |
| 36028450 | Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events. | Urol Oncol | 2022 |
| 35830553 | Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. | J Urol | 2022 |
| 35536148 | Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. | J Urol | 2022 |
| 35536144 | Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. | J Urol | 2022 |
| 35536141 | Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. | J Urol | 2022 |
| 35467778 | Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. | Cancer Med | 2022 |
| 34326126 | A Comprehensive Assessment of <sup>68</sup>Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. | J Nucl Med | 2022 |
| 34516660 | Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. | Cancer | 2022 |
| 34854745 | Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. | J Urol | 2022 |
| 34775795 | Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. | J Urol | 2022 |
| 35015566 | Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. | J Clin Oncol | 2022 |
| 35014711 | Paracrine Wnt signaling is necessary for prostate epithelial proliferation. | Prostate | 2022 |
| 35145197 | Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25â¿¿mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma. | Mod Pathol | 2022 |
| 34593595 | Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. | J Nucl Med | 2022 |
| 35243396 | Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. | Eur Urol Open Sci | 2022 |
| 35176252 | Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. | Hum Pathol | 2022 |
| 34430412 | Preface to "Current and Future Topics on Prostate Cancer". | Translational Andrology and Urology | 2021 |
| 37145399 | Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. | Urol Pract | 2021 |
| 33755225 | Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. | Prostate | 2021 |
| 33473200 | Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. | Nat Genet | 2021 |
| 33471819 | Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. | PLoS One | 2021 |
| 34266741 | 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. | Urologic Oncology: Seminars and Original Investigations | 2021 |
| 33818133 | Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience. Letter. | J Urol | 2021 |
| 33551249 | Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. | Urol Oncol | 2021 |
| 34315659 | A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. | Urologic Oncology: Seminars and Original Investigations | 2021 |
| 34312180 | RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. | Cancer Res | 2021 |
| 33048621 | Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? | J Clin Oncol | 2021 |
| 33373709 | Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. | Urology | 2021 |
| 33148472 | Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. | | 2021 |
| 33237305 | Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer: Is Rising Utilization Justified by Evidence? | JAMA Oncol | 2021 |
| 33160889 | Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. | Clin Genitourin Cancer | 2021 |
| 33398198 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. | Nat Genet | 2021 |
| 34503355 | Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. | J Urol | 2021 |
| 31462701 | The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. | Prostate Cancer Prostatic Dis | 2020 |
| 32145020 | Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. | J Natl Cancer Inst | 2020 |